SCODiA Report by MLBI Lab

Single-Cell Dissection of Breast Cancer Reveals Subtype-Specific Genomic Instability, Immune Modulation, and Stromal Remodeling

This comprehensive single-cell analysis reveals distinct cellular and molecular landscapes across normal breast tissue and its major cancer subtypes: ER+, HER2+, and TNBC. We identified significant genomic instability, including widespread aneuploidy and recurrent CNVs, predominantly within tumor epithelial cells. The study highlights subtype-specific immune microenvironments, with TNBC exhibiting robust immune cell infiltration and a unique macrophage signature, alongside complex cell-cell interaction networks and metabolic reprogramming crucial for tumor progression. These findings provide a granular understanding of breast cancer heterogeneity and uncover potential diagnostic markers and therapeutic targets.

Contents

  1. Dataset overview
  2. UMAP Visualization of scRNA-seq Data Annotations
  3. UMAP Visualization of Major Cell Type Scores, Ploidy Status, and Major Cell Type Annotations
  4. Celltype Subset Marker Expression Analysis
  5. Epithelial Cell Copy Number Variation Analysis in Breast Tissue
  6. CNV-Based UMAPs Revealing Cell Type, Ploidy, and Condition-Specific Genomic Landscapes
  7. Minor Cell Type Population Analysis Across Breast Cancer Subtypes
  8. T Cell and Innate Lymphoid Cell Subsets Exhibit Distinct Distribution Patterns Across Breast Cancer Subtypes
  9. T Cell Subset Population Analysis Across Breast Cancer Conditions
  10. Macrophage Subset Population Analysis in Breast Cancer Subtypes
  11. Macrophage Subset Population Shifts Across Breast Cancer Subtypes
  12. Ploidy Profile of Epithelial Cells Across Breast Cancer Subtypes and Normal Tissue
  13. Breast Cancer Subtype-Specific Cell-Cell Interaction Patterns
  14. Immune Checkpoint and Cell Cycle Gene-Focused Cell-Cell Interactions in HER2+ Breast Cancer and Normal Tissue
  15. Condition-Specific Cell-Cell Interaction Patterns in Breast Cancer Subtypes
  16. Epithelial Cell Condition-Specific Surfaceome Markers in Breast Cancer Subtypes
  17. Macrophage Condition-Specific Surfaceome Markers in Breast Cancer
  18. Fibroblast Condition-Specific Surfaceome Markers in Breast Cancer Subtypes
  19. TNBC 특이적 CD4+ T 세포 표면 마커 분석
  20. Dysregulation of Cell Cycle Gene Expression in Breast Cancer Epithelial Cells Across Subtypes
  21. Gene Ontology (GSA) Analysis of Epithelial Cells in Breast Tissue Across Conditions
  22. 유방암 아형별 상피세포 유전자 세트 농축 분석 (GSEA)
  23. Discussion
  24. Query List

0. Dataset overview

Dataset Summary

분석된 결과: 다음을 포함한 다양한 사전 계산된 분석 결과가 저장되어 있습니다

1. UMAP Visualization of scRNA-seq Data Annotations

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Uniform Manifold Approximation and Projection (UMAP) plots, which are dimensionality reduction visualizations used to represent high-dimensional single-cell RNA sequencing (scRNA-seq) data in a 2D space. Each UMAP plot is colored by a different metadata annotation from the AnnData object, including condition, sample, celltype_major, celltype_minor, ploidy_dec, and celltype_subset. These visualizations are crucial for assessing the overall structure of the dataset, evaluating the quality of cell type annotations, and understanding how biological and technical factors contribute to cellular heterogeneity.

Visual Summary

Condition

The UMAP colored by condition (Normal, TNBC, HER2+, ER+) shows clear separation between normal and tumor samples. The "Normal" cells (light green) primarily cluster in distinct regions, suggesting a unique transcriptional state compared to cancer cells. Tumor conditions (ER+, HER2+, TNBC) largely overlap in several regions but also form some condition-specific clusters. For instance, TNBC (dark blue) appears somewhat distinct from ER+ (maroon) and HER2+ (orange) in certain areas, particularly in a dense cluster at the bottom. This indicates that while there's shared transcriptional landscape among different breast cancer subtypes, specific molecular differences drive their separation in the UMAP space.

Sample

The sample UMAP displays a high degree of sample mixing across the different clusters. While some smaller clusters might be enriched for specific samples, the overall impression is that cells from different samples generally intermingle within their respective major cell type groups and conditions. This is a positive indication, suggesting that technical batch effects between samples are not the dominant factor shaping the global UMAP structure, and biological signals (like cell type or condition) are primarily driving the observed separation.

Celltype Major

The celltype_major UMAP shows excellent separation of major cell types. Distinct, well-defined clusters correspond to Epithelial cells (Epi, orange), Stromal cells (teal), T cells (dark blue), Myeloid cells (light green), Endothelial cells (Endo, red), B cells (maroon), and Mast cells (yellow-green). This robust clustering validates the quality of the major cell type annotations and indicates substantial transcriptional differences between these broad cell lineages. The large "Epi" cluster is particularly prominent, consistent with the tissue: Breast and Tumor origin celltype: Epithelial cell context, as epithelial cells are abundant in breast tissue and are the origin of breast cancers.

Celltype Minor

The celltype_minor UMAP provides a more granular view, showing further subdivisions within the major cell types. For example, the major Epithelial cell cluster is now seen to contain "Epithelial cell" (orange) and other minor types that likely stem from it or are intermingled. Similarly, distinct clusters are visible for T cell CD4+ (dark blue) and T cell CD8+ (light blue), and Macrophages (yellow) within the Myeloid cell cluster. This finer resolution confirms the heterogeneity within major cell populations and the precision of the minor cell type assignments.

Ploidy_dec

The ploidy_dec UMAP (Aneuploid, Diploid, Unclear) reveals a striking pattern. "Aneuploid" cells (maroon) are predominantly clustered in regions that overlap significantly with cancer-associated epithelial cell clusters, especially those observed to be distinct in the condition UMAP (e.g., the bottom-left cluster with high ER+ and TNBC representation). "Diploid" cells (light yellow) are more broadly distributed, intermingling with both normal and tumor-associated stromal and immune cell clusters, as expected for non-cancerous cells. The distinct segregation of aneuploid cells suggests that this chromosomal abnormality is a strong biological signal driving the separation of cancer cells from other cell types and normal cells.

Celltype Subset

The celltype_subset UMAP provides the most detailed view of cell populations. It confirms and further refines the distinctions seen in celltype_minor and celltype_major plots. For instance, within the epithelial compartment, "Luminal epithelial cell" (Epi (Lum), orange) and "Mammary epithelial cell" (Epi (Mam), lighter orange) are visible. Immune cell subsets like various macrophage subtypes (Mac_M1, Mac_M2A, etc.), T cell subtypes (T_Naive, T_Th1, T_Treg, T_Cyto), and B cell subtypes (B cell (Memory), B cell (Follicular)) form distinct yet sometimes interconnected clusters, reflecting the complexity of the immune microenvironment. The clear separation of these fine-grained cell types underscores the quality and resolution of the cell type annotation.

Biological Interpretation

The UMAP visualizations collectively paint a comprehensive picture of the cellular landscape in human breast tissue, encompassing both normal and different breast cancer subtypes.

  1. Tumor vs. Normal Separation: The clear separation of "Normal" cells from all "Tumor" conditions in the condition UMAP highlights fundamental transcriptional differences between healthy and malignant breast tissues. This is expected, as cancer development involves extensive transcriptional reprogramming.
  2. Tumor Heterogeneity: While distinct from normal, the overlap and intermingling of ER+, HER2+, and TNBC cells in the condition UMAP suggest shared biological features among these cancer subtypes, particularly within the tumor microenvironment (TME) or certain epithelial states. However, the presence of condition-specific clusters within the larger tumor mass also indicates subtype-specific molecular signatures, consistent with the known distinct clinical and molecular characteristics of these breast cancer types PubMed Search: Breast cancer subtypes molecular characteristics.
  3. Robust Cell Type Identification: The excellent separation of major and minor cell types confirms high-quality cell type annotation based on gene expression profiles. This is crucial for downstream analyses, ensuring that differential gene expression or cell-cell interaction analyses are performed on biologically meaningful cell populations. The presence of specific epithelial (Luminal, Mammary), stromal (Fibroblast, Smooth muscle cell), endothelial (Endothelial cell, Lymphatic Endothelial cell), and diverse immune cell subsets (Macrophages, T cells, B cells, ILCs) reflects the complexity of the breast tissue microenvironment GeneCards: Fibroblast.
  4. Aneuploidy as a Cancer Signature: The strong co-localization of "Aneuploid" cells with clusters dominated by tumor conditions and specifically by "Epithelial cell" populations is highly significant. Since Epithelial cells are the "Tumor origin celltype" and aneuploidy is a hallmark of cancer, this observation strongly supports the accurate identification of malignant epithelial cells. Aneuploidy contributes to genomic instability and is a major driver of tumor evolution and heterogeneity PubMed Search: Aneuploidy cancer hallmark.
  5. Minimal Batch Effects: The effective mixing of cells from different sample IDs within their respective cell type and condition clusters is a positive indicator that technical variations are not obscuring biological signals, strengthening the reliability of the observed biological patterns.

Annotation Notes

The UMAP plots demonstrate that the current annotations for condition, sample, celltype_major, celltype_minor, ploidy_dec, and celltype_subset are well-supported by the underlying gene expression data. The distinct clustering and biological coherence observed across these varied annotations suggest high confidence in the cell identity assignments and the ability to differentiate between normal and cancerous states, as well as between different cancer subtypes. The ploidy inference further strengthens the identification of malignant cells, providing an important layer of validation for cancer cell annotation.

2. UMAP Visualization of Major Cell Type Scores, Ploidy Status, and Major Cell Type Annotations

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis provides a UMAP visualization of single-cell RNA-seq data, displaying the distribution of major cell type scores (derived from HiCAT), ploidy inference results, and the final major cell type annotations across the cellular landscape. These plots are crucial for assessing the quality of cell type assignments and understanding the overall cellular heterogeneity and genomic stability within the dataset.

Visual Summary

The UMAP plots illustrate the embedding of 85,449 cells into a 2-dimensional space, revealing distinct clusters and cellular neighborhoods.

Major Cell Type Scores (HiCAT_major_score)

Ploidy Status (ploidy_dec)

Major Cell Type Annotations (celltype_major)

Biological Interpretation

The UMAP visualizations provide a comprehensive overview of the cellular landscape in the breast tissue single-cell RNA-seq data, encompassing various conditions including Normal, TNBC, HER2+, and ER+.

  1. Cellular Heterogeneity: The distinct clustering of various major cell types (Epithelial, Stromal, Endothelial, Myeloid, T, B, Mast cells) confirms the high cellular heterogeneity characteristic of breast tissue, especially in the context of cancer where immune and stromal cell infiltration is common.
  2. Robust Cell Type Annotation: The strong correspondence between the HiCAT_major_score plots and the celltype_major annotation plot indicates that the automated scoring method effectively captures the defining gene expression signatures of each major cell type. This suggests a high confidence in the assigned cell type labels for subsequent analyses.
  3. Aneuploidy in Epithelial Cells: A significant biological insight emerges from the comparison of ploidy_dec with celltype_major. The aneuploid cells largely co-localize with the epithelial cell cluster. Given that the "Tumor origin celltype" is Epithelial cell and the dataset includes breast cancer samples (TNBC, HER2+, ER+), this observation strongly suggests that the aneuploid cells represent the malignant epithelial cell population within the tumor microenvironment. Aneuploidy is a hallmark of cancer and indicates genomic instability, which is a key driver of tumor progression GeneCards: Aneuploidy.
  4. Distinct Immune and Stromal Compartments: Immune cells (T cells, B cells, Myeloid cells, Mast cells) and stromal cells (Fibroblasts, Smooth muscle cells, Endothelial cells) form distinct, well-separated clusters, highlighting their unique transcriptomic profiles and specialized functions within the tissue. This compartmentalization is expected in complex tissues like the breast, and their interactions are critical in both normal physiology and disease.
  5. Mast Cell Distribution: Mast cells appear to be a smaller population, more dispersed or forming less compact clusters compared to other major cell types. Their scores are also on a smaller scale. This could reflect their relative abundance or their scattered distribution within the tissue.

Annotation Notes

The consistency between the HiCAT_major_score visualizations and the celltype_major annotations confirms the quality and reliability of the automated cell type assignments. The plot_umap with major_type_score successfully serves its purpose as an annotation-checking and overview tool. The clear separation of cell types on the UMAP, supported by specific scores, indicates that the initial dimensionality reduction and clustering steps have effectively resolved distinct cellular identities. The distribution of aneuploidy strongly supports the identification of tumor cells within the epithelial compartment, which is a critical finding for cancer-related studies.

3. Celltype Subset Marker Expression Analysis

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis visualizes the expression of marker genes across various celltype_subset annotations derived from the single-cell RNA-seq data. The dot plot serves as a critical quality control step to validate cell type assignments by assessing the specificity and enrichment of known marker genes within each defined cell population. The size of each dot represents the fraction of cells within a given celltype_subset that express a particular gene, while the color intensity indicates the mean expression level of that gene within the group. The red boxes highlight groups of genes with high specificity to a particular cell type or closely related cell types.

Visual Summary

The dot plot clearly illustrates distinct expression patterns for numerous marker genes across the 37 identified celltype_subset populations. Key observations include:

Biological Interpretation

The observed marker expression patterns strongly support the biological fidelity of the celltype_subset annotations in this breast tissue dataset.

Annotation Notes

The comprehensive and largely distinct marker expression patterns observed across the celltype_subset populations provide strong evidence for the quality and reliability of the cell type annotations. The identification of specific marker genes for each subset, consistent with established biological knowledge for breast tissue, indicates robust cell clustering and annotation. The hierarchical nature of marker expression, where broader lineage markers are shared and subset-specific markers provide granular resolution, further validates the annotation strategy. This high confidence in cell identity is crucial for downstream analyses, such as differential expression and cell-cell interaction studies, ensuring that biological conclusions are drawn from accurately defined cellular populations.

4. Epithelial Cell Copy Number Variation Analysis in Breast Tissue

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates copy number variations (CNVs) in Epithelial cells from human breast tissue, encompassing various conditions (Normal, TNBC, HER2+, ER+). The plot_cnv_heatmap tool was used to visualize log2(Copy Number Ratio, CNR) values across genomic regions, grouped by sample and ploidy status, and to summarize frequently amplified cytogenetic bands. This provides insights into the genomic instability and subtype-specific alterations within the tumor-origin cell type.

Visual Summary

1. Copy Number Ratio Heatmap (log2(CNR))

The primary heatmap displays log2(CNR) values for Epithelial cells across approximately 2200 genomic spots, ordered by chromosome (1 to 22). Samples are grouped along the y-axis by their inferred ploidy status (Diploid, Aneuploid - implicitly for samples without explicit "Diploid" prefix) and condition/sample identifier (e.g., Diploid ER-MH0019, HER2-MH0031, N-MH0023-Total).

2. Significant Amplifications Summary Heatmap

This heatmap summarizes the frequency of significantly amplified cytogenetic bands across the analyzed tumor samples. The color intensity and numerical values within each cell represent the percentage of cells within that sample showing amplification in the specific band. The bar plot on the right displays the overall frequency of each cytogenetic band amplification across all samples.

Biological Interpretation

The analysis of Epithelial cells, the tumor-origin cell type in breast cancer, reveals significant genomic alterations. Normal samples serve as a clear baseline with largely diploid genomes. In contrast, tumor samples, especially those designated as aneuploid, display extensive and recurrent CNVs.

Clinical or Translational Implications

5. CNV-Based UMAPs Revealing Cell Type, Ploidy, and Condition-Specific Genomic Landscapes

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents UMAP visualizations derived from Copy Number Variation (CNV) estimates, colored by major cell type, minor cell type, ploidy status, disease condition, and individual sample. The primary goal is to assess how CNV patterns delineate distinct cellular populations, genomic states, and disease contexts within the single-cell RNA-seq dataset of breast tissue. These plots provide a foundational overview of the dataset's genomic architecture and help validate cell type annotations in the context of malignancy.

Visual Summary

Cell Type Distribution on CNV UMAPs

Ploidy Status and Genomic Stability

Condition-Specific CNV Signatures

Inter-Sample CNV Heterogeneity

Biological Interpretation

The CNV-based UMAP embedding provides critical insights into the genomic landscape of breast tissue cells, reinforcing several fundamental biological principles:

Annotation Notes

The UMAPs provide strong support for the quality and consistency of cell type and ploidy annotations. The distinct clustering of different cell types and the clear separation of aneuploid (tumor) from diploid (non-malignant) populations are consistent with known breast biology and cancer genomics. This confirms that the estimated CNV profiles effectively capture biologically meaningful distinctions at the single-cell level. The relatively small proportion of "Unclear" ploidy calls suggests a high confidence in the overall ploidy classification.

6. Minor Cell Type Population Analysis Across Breast Cancer Subtypes

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a stacked bar plot visualizing the relative proportions of different minor cell types within individual samples across four breast conditions: ER-positive (ER+), HER2-positive (HER2+), Normal, and Triple-negative breast cancer (TNBC). The cell type populations are normalized to 100% for each sample, allowing for a direct comparison of the cellular composition of the tumor microenvironment and normal tissue.

Visual Summary

The stacked bar plot clearly illustrates the cellular heterogeneity within and between different breast tissue conditions.

Immune cell infiltration varies significantly by condition

Biological Interpretation

The observed cell type distributions provide critical insights into the distinct microenvironments of normal breast tissue and different breast cancer subtypes.

Heterogeneous Immune Infiltration in Breast Cancer Subtypes

Clinical or Translational Implications

Understanding the distinct cellular compositions of breast cancer subtypes has significant clinical and translational implications:

Therapeutic Strategies

7. T Cell and Innate Lymphoid Cell Subsets Exhibit Distinct Distribution Patterns Across Breast Cancer Subtypes

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis utilizes single-cell RNA-seq data from human breast tissue to visualize the population distribution of T cell and innate lymphoid cell (ILC) subsets across different breast cancer conditions (ER+, HER2+, TNBC) and normal breast tissue samples. The stacked bar plots illustrate the relative proportions of various cell types, including ILC1, ILC2, ILC3 (NCR+), ILC3 (NCR-), ILCreg, LTI, NK cells, and diverse T cell subsets (Cytotoxic, Naive, Tfh, Th1, Th17, Th2, Th22, Th9, Treg, and unassigned cells) within the broader "T cell major" category for each individual sample.

Visual Summary

The visualization reveals striking differences in the relative abundance of T cell and ILC subsets across the four conditions: Normal, ER+, HER2+, and TNBC.

Biological Interpretation

The observed shifts in T cell and ILC subset populations underscore the distinct immunological microenvironments characteristic of different breast cancer subtypes and normal tissue.

Clinical or Translational Implications

These findings have several potential clinical and translational implications:

8. T Cell Subset Population Analysis Across Breast Cancer Conditions

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the proportions of various T cell and innate lymphoid cell (ILC) subsets within breast tissue across different conditions: Normal, ER+ (Estrogen Receptor positive), HER2+ (Human Epidermal Growth Factor Receptor 2 positive), and TNBC (Triple-Negative Breast Cancer). Box plots visualize the distribution of each cell type's proportion, and pairwise statistical comparisons (p-values) highlight significant differences between conditions. The goal is to identify distinct immune microenvironment compositions associated with different breast cancer subtypes.

Visual Summary

The box plots reveal several statistically significant shifts in T cell and ILC subset proportions across the analyzed breast tissue conditions:

Biological Interpretation

The observed shifts in T cell and ILC subset proportions highlight dynamic changes in the immune microenvironment across different breast cancer subtypes.

  1. Reduction of Homeostatic/Immune-Regulatory Cells in Cancer: The significant decrease in LTI cells, ILC3(-), and ILCreg in tumor conditions compared to normal tissue is notable.
  1. Increased Effector and Helper T Cells in Cancer: Conversely, most cancer subtypes, particularly ER+, HER2+, and TNBC, show increased proportions of various T helper and cytotoxic T cell subsets.

Clinical or Translational Implications

These findings have several potential clinical and translational implications for breast cancer:

References

[1] Pylayeva-Gupta, Y., et al. (2016). Role of tertiary lymphoid structures in cancer. *Immunity, 45*(4), 734-744. PubMed Search: "tertiary lymphoid structures cancer" - PubMed

[2] Klose, C. S., & Artis, D. (2016). Innate lymphoid cells in cancer. *Nature Immunology, 17*(7), 777-781. PubMed Search: "innate lymphoid cells cancer review" - PubMed

[3] Savas, P., et al. (2016). Clinical impact of immune infiltrates in breast cancer. *Nature Reviews Clinical Oncology, 13*(4), 232-247. PubMed Search: "TILs breast cancer immunotherapy" - PubMed

[4] Glimcher, L. H., et al. (2004). The T-bet-dependent developmental program of Th1 T cells. *Immunity, 20*(6), 669-673. PubMed Search: "Th1 anti-tumor immunity" - PubMed

[5] Chtanova, T., et al. (2004). T follicular helper cells and the B cell response. *Nature Immunology, 5*(9), 882-888. PubMed Search: "T follicular helper cells cancer" - PubMed

[6] Kryczek, I., et al. (2007). IL-17 and Th17 cells in cancer. *Nature Immunology, 8*(3), 227-233. PubMed Search: "Th17 cells cancer review" - PubMed

[7] Emens, L. A. (2018). Breast Cancer Immunotherapy: Facts and Hopes. *Clinical Cancer Research, 24*(3), 511-520. PubMed Search: "breast cancer immunotherapy subtypes" - PubMed

9. Macrophage Subset Population Analysis in Breast Cancer Subtypes

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the proportional distribution of different macrophage subsets (M1, M2A, M2B, M2C, M2D) across various breast tissue conditions: Normal, Estrogen Receptor-positive (ER+), Human Epidermal growth factor Receptor 2-positive (HER2+), and Triple-Negative Breast Cancer (TNBC). The goal is to understand the composition of the macrophage compartment within the tumor microenvironment (TME) and normal breast tissue, providing insights into condition-associated biology and potential cell-state shifts. The celltype_subset column, which categorizes macrophages into these specific M1/M2 subtypes, was utilized for this population analysis at the sample level.

Visual Summary

The stacked bar plots display the relative proportions of five macrophage subsets (M1, M2A, M2B, M2C, M2D) within each individual sample, grouped by condition.

Breast Cancer Subtypes (ER+, HER2+, TNBC):

Subtype-Specific Trends & Heterogeneity:

Biological Interpretation

Macrophages are critical components of the tumor microenvironment (TME) and can exert both pro- and anti-tumor functions, typically categorized into M1-like (pro-inflammatory, anti-tumor) and M2-like (anti-inflammatory, pro-tumor) phenotypes. The observed distribution of macrophage subsets offers important biological insights:

  1. Persistent M1-like Macrophages in Cancer: The sustained presence of M1 macrophages in breast cancer samples suggests an ongoing immune attempt to combat the tumor, or that the M1 classification here may encompass diverse activation states not fully indicative of strong anti-tumor activity in all contexts. M1 macrophages are known for producing pro-inflammatory cytokines (e.g., TNF-α, IL-1β) and reactive nitrogen/oxygen species, crucial for pathogen clearance and tumor cell killing [1]. Their prevalence, even in cancer, could indicate areas of immune activation or complex regulatory mechanisms at play.
  2. Diverse M2 Polarization in the TME: The consistent presence of M2A, M2B, M2C, and M2D macrophages in all breast cancer subtypes highlights the heterogeneous and often pro-tumorigenic roles of these cells.
  1. No Simple M1-to-M2 Switch: The data does not support a universal and complete shift from M1 to M2 dominance in breast cancer compared to normal tissue. Instead, it indicates a complex interplay where M1 cells persist alongside varying proportions of pro-tumorigenic M2 subsets. This implies that the TME might contain a mixture of macrophage activation states, or that specific M2 subtypes are preferentially enriched rather than a complete polarization overhaul. This complexity is often observed in scRNA-seq studies where macrophage states are more fluid and heterogeneous than a simple M1/M2 dichotomy.

Clinical or Translational Implications

Understanding the precise composition of macrophage subsets within the breast cancer TME has significant clinical and translational implications:

References

  1. M1 Macrophages: Gordon, S., & Martinez, F. O. (2010). Alternative activation of macrophages: mechanisms and functions. *Immunity*, 32(5), 593-604. PubMed Search: M1 macrophage function cancer
  2. M2A Macrophages: Martinez, F. O., Sica, A., Mantovani, A., & Locati, M. (2008). Macrophage activation by cytokines. *Current Opinion in Immunology*, 20(2), 177-183. PubMed Search: M2A macrophage cancer
  3. M2B Macrophages: Mantovani, A., Sica, A., Allavena, F., Rubeis, C. D., & Locati, M. (2009). Tumor-associated macrophages and the tumor microenvironment. *Immunity*, 30(2), 200-212. PubMed Search: M2B macrophage cancer
  4. M2C Macrophages: Orecchioni, S., et al. (2019). Macrophage Polarization and Tumor Microenvironment. *Genes*, 10(7), 548. PubMed Search: M2C macrophage cancer
  5. M2D Macrophages (TAMs): Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012). Coordinated regulation of myeloid cells by tumours. *Nature Reviews Immunology*, 12(4), 253-268. PubMed Search: M2D macrophage angiogenesis tumor
  6. Therapeutic Targeting of Macrophages: Pathria, P., Louis, T. L., &‐Babu, K. G. (2019). Macrophage polarization in cancer: a new paradigm for anticancer therapy. *Trends in immunology*, 40(6), 540-553. PubMed Search: macrophage reprogramming cancer therapy

10. Macrophage Subset Population Shifts Across Breast Cancer Subtypes

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents box plots illustrating the proportional distribution of various macrophage subsets – Macrophage (M1), Macrophage (M2A), Macrophage (M2B), and Macrophage (M2D) – across different breast cancer conditions: Normal, ER+ (Estrogen Receptor positive), TNBC (Triple-Negative Breast Cancer), and HER2+ (HER2 positive). The goal is to identify statistically significant differences in these immune cell populations that may contribute to the distinct microenvironments of these cancer types. The comparisons are made against the 'Normal' condition as a reference.

Visual Summary

The box plots reveal distinct patterns in macrophage subset proportions:

Macrophage (M1) Proportions

Macrophage (M2B) Proportions

Macrophage (M2D) Proportions

Macrophage (M2A) Proportions

Biological Interpretation

Macrophages are highly plastic immune cells that polarize into different functional states, broadly categorized as M1 (pro-inflammatory, tumoricidal) and M2 (anti-inflammatory, pro-tumorigenic, tissue repair). The observed shifts in macrophage subset populations suggest significant alterations in the immune landscape of breast cancer compared to normal tissue.

  1. Elevated M1 Macrophages in Cancer: The consistent increase in M1 macrophage proportions across all breast cancer subtypes is a notable finding. M1 macrophages are traditionally associated with anti-tumor immunity, characterized by the production of pro-inflammatory cytokines (e.g., TNF-α, IL-12) and potent antigen presentation capabilities. This elevation could indicate an active, but potentially ineffective or suppressed, anti-tumor immune response within the tumor microenvironment. Alternatively, it might reflect a chronic inflammatory state that, in some contexts, can paradoxically fuel tumor progression.
  2. Decreased M2B Macrophages in Cancer: The significant reduction of M2B macrophages across all cancer conditions is intriguing. M2B macrophages exhibit a mixed M1/M2 phenotype and are implicated in immunoregulatory functions, secreting both pro- and anti-inflammatory mediators. Their decrease might shift the overall immunoregulatory balance in the tumor microenvironment, potentially reducing certain immunosuppressive or pro-tumorigenic signals historically associated with this subset, or suggesting that other cell types or macrophage subsets compensate for these roles.
  3. Decreased M2D Macrophages in TNBC and HER2+: M2D macrophages are often considered a prominent phenotype of tumor-associated macrophages (TAMs), known for promoting angiogenesis, immune suppression, and tumor progression. The observed trend of lower M2D proportions in aggressive subtypes like TNBC and HER2+ compared to normal tissue is somewhat unexpected, as these cancers often exhibit highly immunosuppressive microenvironments. This finding could imply:
  1. Stable M2A Macrophages: The lack of significant change in M2A macrophage proportions suggests that this particular wound-healing/pro-tumor subset does not undergo major proportional shifts across the studied conditions in breast cancer.

Collectively, these findings highlight a dynamic and complex reprogramming of macrophage populations within the breast tumor microenvironment. The observed shifts (increased M1, decreased M2B, and decreased M2D in certain subtypes) suggest that the immunological landscape of breast cancer, even across different subtypes, is distinct from normal tissue.

Clinical or Translational Implications

The differential proportions of macrophage subsets in breast cancer conditions carry potential clinical implications:

Further research involving functional assays and absolute cell quantification would be essential to elucidate the precise roles of these shifting macrophage populations in breast cancer pathogenesis and response to therapy.

Macrophage polarization and cancer: PubMed Search

11. Ploidy Profile of Epithelial Cells Across Breast Cancer Subtypes and Normal Tissue

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis visualizes the ploidy status (Aneuploid or Diploid) of Epithelial cells, identified as the tumor origin cell type, across individual samples from different breast tissue conditions: ER+ breast cancer, HER2+ breast cancer, Triple-Negative Breast Cancer (TNBC), and Normal breast tissue. The plot_celltype_population tool was used to generate a stacked bar plot, with each bar representing a sample and showing the proportion of Epithelial cells classified as Aneuploid (maroon) or Diploid (orange).

Visual Summary

The bar plot effectively illustrates the ploidy distribution within Epithelial cells across various samples and conditions:

Biological Interpretation

The observed ploidy patterns strongly align with the known genomic characteristics of normal and cancerous breast tissues, given that Epithelial cells are identified as the "Tumor origin celltype" in this dataset.

  1. Normal Tissue Homeostasis: The consistent diploidy in Epithelial cells from normal breast tissue samples reflects the genomic stability characteristic of healthy, non-malignant cells. This serves as a critical baseline and validates the ploidy inference method's ability to distinguish healthy from diseased states.
  2. Aneuploidy as a Hallmark of Cancer: In stark contrast to normal tissue, Epithelial cells within ER+, HER2+, and TNBC samples frequently exhibit high levels of aneuploidy. Aneuploidy, the presence of an abnormal number of chromosomes, is a well-established hallmark of cancer, indicating genomic instability and often correlating with malignant transformation and tumor progression [Cancer Res. 2011;71(14):4796-805, PubMed search: aneuploidy cancer hallmark]. This observation supports the identification of these epithelial cells as neoplastic components of the tumors.
  3. Subtype-Specific Genomic Instability:

Clinical or Translational Implications

The ploidy status of Epithelial cells, especially the presence and degree of aneuploidy, carries important clinical and translational implications:

  1. Diagnostic and Prognostic Biomarker: Aneuploidy, particularly in the tumor-originating epithelial cells, can serve as a valuable diagnostic marker distinguishing malignant from benign lesions. Furthermore, the *degree* of aneuploidy (e.g., high versus low) often correlates with tumor aggressiveness, risk of recurrence, and overall patient prognosis in breast cancer [J Clin Oncol. 2008;26(18):2966-73, PubMed search: breast cancer aneuploidy prognosis].
  2. Therapeutic Stratification: Identifying highly aneuploid tumors could guide therapeutic decisions. Cancers with high levels of genomic instability, often associated with aneuploidy, may exhibit specific vulnerabilities (e.g., dependence on DNA repair pathways, increased sensitivity to certain chemotherapies) that can be exploited by targeted therapies [Nat Rev Drug Discov. 2017;16(8):529-47]. Conversely, diploid tumors might respond differently to standard treatments.
  3. Personalized Medicine in ER+ Cancer: The considerable heterogeneity in ploidy observed within ER+ breast cancer emphasizes the need for a more granular characterization of these tumors. Relying solely on ER status might obscure important biological differences. Incorporating ploidy analysis could help stratify ER+ patients into distinct risk groups or predict response to specific treatments, moving towards more personalized therapeutic strategies.
  4. Further Investigation: This analysis provides a high-level view of ploidy. Further detailed investigation using the provided obsm['X_cnv'] data (CNV estimates) would be crucial to identify specific chromosomal gains or losses driving the aneuploidy in different cancer subtypes, potentially revealing novel therapeutic targets or resistance mechanisms.

12. Breast Cancer Subtype-Specific Cell-Cell Interaction Patterns

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates cell-cell interaction (CCI) patterns within the breast tumor microenvironment (TME) across different breast cancer subtypes (ER+, HER2+, TNBC) and compares them to normal breast tissue. The focus is on interactions involving key cellular components of the TME: Epithelial cells (distinguished by ploidy as Diploid or Aneuploid), Fibroblasts, Macrophages, and T cells (CD4+, CD8+). The analysis utilizes CellPhoneDB results, visualizing significant ligand-receptor pairs based on their p-value (dot size) and mean expression level (color intensity). By comparing these patterns, we aim to uncover subtype-specific communication hubs that may drive tumor progression or offer therapeutic opportunities.

Visual Summary

CCI for ER+

The plot for ER+ breast cancer primarily highlights significant interactions between Macrophages (Mac) and Epithelial cells, especially Aneuploid Epithelial cells (Aneuploid Epi), which are likely the cancerous population. Key interactions include reciprocal signaling of NAMPT-NOX2_complex, PLAU-PLAUk, PPIA-BSG, and TYROBP-CD44 between Macrophages and Aneuploid Epithelial cells. Additionally, the immune checkpoint interaction LGALS9-HAVCR2 is prominent in both Mac|Aneuploid Epi and Aneuploid Epi|Mac interactions. Macrophage-macrophage interactions involving APOE-TREM2_receptor and CLU-TREM2_receptor are also notable.

CCI for HER2+

HER2+ breast cancer exhibits a more diverse interaction landscape involving T cells (CD4+, CD8+), Macrophages, and Epithelial cells (Diploid and Aneuploid). Similar to ER+, NAMPT-NOX2_complex, PLAU-PLAUk, PPIA-BSG, TYROBP-CD44, and LGALS9-HAVCR2 interactions are strongly observed between Macrophages and Aneuploid Epithelial cells. Furthermore, T cell interactions are prominent: CD86-CTLA4 between T CD4+ cells (suggesting T cell regulation) and TGFB1-TGFBR1 between T CD8+ cells and Aneuploid Epithelial cells (indicating immunosuppression). A notable feature in HER2+ is the extensive presence of cholesterol metabolism-related interactions (e.g., Desmosterol_byDHCR7_NR1H2, Cholesterol_byDHCR7_RORA) involving Macrophages and Epithelial cells, along with angiogenic signaling like VEGFA-NRP1.

CCI for Normal

The normal breast tissue microenvironment shows interactions predominantly between Fibroblasts (Fib) and Diploid Epithelial cells (Diploid Epi). This plot is characterized by numerous extracellular matrix (ECM) related interactions involving various integrin complexes (e.g., COL1A1-integrin_a2b1_complex, FN1-integrin_avb3_complex, LAMA3-integrin_a3b1_complex) and several growth factor signaling pathways (e.g., AREG-EGFR, EGF-EGFR, FGF2-FGFR1, HGF-MET). These patterns reflect the fundamental processes of tissue structural maintenance, cell growth, and differentiation in a healthy state.

CCI for TNBC

In TNBC, interactions are largely concentrated between Macrophages and Epithelial cells, particularly Aneuploid Epithelial cells. The recurring pro-tumorigenic interactions seen in ER+ and HER2+, such as NAMPT-NOX2_complex, PLAU-PLAUk, PPIA-BSG, TYROBP-CD44, and the immune checkpoint LGALS9-HAVCR2, are also highly significant here. Additionally, desmosomal adhesion molecules (e.g., DSG2-DSC3, DSG2-DSG1) appear to be involved in interactions among Aneuploid Epithelial cells, alongside Notch pathway component JAG1-CD46.

Biological Interpretation

Shared Cancer-Associated Interactions

Across all three breast cancer subtypes (ER+, HER2+, TNBC), a core set of highly significant and strongly expressed cell-cell interactions involving Macrophages and Aneuploid Epithelial cells emerges, contrasting sharply with the normal tissue profile. These include:

Subtype-Specific Interaction Landscapes

While common themes exist, subtype-specific interactions provide insights into distinct biological characteristics:

Role of Ploidy in Tumor Interactions

The distinction between 'Diploid Epi' and 'Aneuploid Epi' is critical. Interactions involving 'Aneuploid Epi' cells (likely representing tumor cells, given that Epithelial cells are the 'Tumor origin celltype' and aneuploidy is a hallmark of cancer) are consistently associated with pro-tumorigenic and immunosuppressive pathways across all cancer subtypes. This highlights the crucial role of genomic instability and tumor cell transformation in shaping the pathological cell-cell communication networks within the TME.

Normal Tissue Homeostasis

The 'Normal' condition serves as a healthy baseline, characterized by robust interactions between Fibroblasts and Diploid Epithelial cells. The dominance of integrin-ECM interactions (e.g., involving collagen, fibronectin, laminin) and diverse growth factor signaling (e.g., EGFR, FGFR, MET, IGF1R) underscores their essential roles in maintaining tissue architecture, cellular differentiation, and growth regulation in a healthy breast. These patterns are largely disrupted or superseded by pathological interactions in cancer.

Clinical or Translational Implications

The identified cell-cell interaction patterns offer several avenues for clinical and translational applications:

Therapeutic Target Prioritization:

Biomarker Development:

Experimental Validation:

13. Immune Checkpoint and Cell Cycle Gene-Focused Cell-Cell Interactions in HER2+ Breast Cancer and Normal Tissue

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates cell-cell interactions (CCI) mediated by a curated set of genes associated with immune checkpoint and cell cycle pathways. The plot_cci_dots tool was used to visualize these interactions, displaying significant ligand-receptor pairs between various cell types, with interactions aggregated by condition (HER2+ vs. Normal). The size of the dots represents the negative log10 of the p-value (significance), and the color intensity reflects the log2 of the mean expression/interaction score, indicating the strength of the interaction.

Visual Summary

CCI for HER2+ Condition:

Key ligand-receptor interactions observed include

CCI for Normal Condition:

Key ligand-receptor interactions observed include

Biological Interpretation

Differences between HER2+ and Normal Conditions:

  1. Cellular Context:
  1. Pathway Dominance:
  1. Missing Immune Checkpoint Signals: While the query included specific immune checkpoint genes like CD274 (PD-L1) and PDCD1 (PD-1), these are not prominently displayed in the resulting plots. This suggests that either their interactions did not meet the statistical cutoffs (pval_cutoff=0.05, mean_cutoff=0.01) in this specific analysis, or other immune-modulating pathways like TGF-β are more dominant in terms of significant intercellular communication involving the selected gene list.

Clinical or Translational Implications

The distinct patterns of cell-cell interactions observed in HER2+ breast cancer compared to normal tissue offer potential avenues for therapeutic intervention and diagnostic biomarker development.

  1. Targeting TGF-β Signaling in HER2+ Breast Cancer:
  1. Modulating T Cell Activity in HER2+ Breast Cancer:
  1. Biomarker Potential:

In summary, this analysis highlights the critical role of TGF-β-mediated immune modulation and T cell signaling within the HER2+ breast cancer microenvironment, contrasting it with EGFR- and TGF-β-driven homeostatic interactions in normal tissue. These findings underscore the potential for targeting specific cell-cell communication pathways to develop more effective treatments for HER2+ breast cancer.

14. Condition-Specific Cell-Cell Interaction Patterns in Breast Cancer Subtypes

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates condition-specific cell-cell interaction (CCI) patterns involving major immune and stromal cell types (T cell, B cell, Myeloid cell, Mast cell, Stromal cell, Endothelial cell) across different breast cancer conditions (ER+, HER2+, TNBC) and normal breast tissue samples. The results are presented as a dot plot, where the size of each dot reflects the statistical significance of the interaction (larger dot = smaller p-value, more significant), and the color intensity represents the scaled strength of the interaction (darker red = stronger interaction). The aim is to identify CCIs that significantly differ between conditions, providing insight into the unique communication landscape of each breast cancer subtype and normal tissue.

Visual Summary

The dot plot visualizes a complex landscape of cell-cell interactions, organized by individual samples within each major breast cancer subtype (ER+, HER2+, TNBC) and Normal condition.

Prominent Interaction Categories

Biological Interpretation

The observed condition-specific CCI patterns reveal distinct biological programs active in the tumor microenvironment of different breast cancer subtypes.

[1] GeneCards: Integrin alpha V, GeneCards: Integrin beta 1

[2] PubMed search: "integrin cancer progression metastasis"

These findings suggest that TNBC has a highly immune-active yet potentially immunosuppressive microenvironment, characterized by a complex interplay between macrophages and T cells.

[3] GeneCards: CD86

[4] GeneCards: CTLA4

[5] GeneCards: HLA-F

[6] GeneCards: CD58

[7] PubMed search: "VEGFA breast cancer angiogenesis"

[8] GeneCards: CXCL12, GeneCards: CXCR4

Distinct Profiles across Subtypes

Clinical or Translational Implications

The condition-specific CCI patterns provide valuable insights for breast cancer diagnosis, prognosis, and therapeutic development:

Targeted Therapies

15. Epithelial Cell Condition-Specific Surfaceome Markers in Breast Cancer Subtypes

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis aimed to identify surfaceome markers specifically expressed in Epithelial cells across different breast tissue conditions: Normal, ER+ breast cancer, HER2+ breast cancer, and Triple-Negative Breast Cancer (TNBC). By focusing on surface proteins, this study seeks to pinpoint potential diagnostic biomarkers and therapeutic targets that are readily accessible for drug development. The dot plot visualizes the expression of up to 50 curated surfaceome markers for each condition, considering both the mean expression level and the fraction of cells expressing the marker within each sample, which are further stratified by ploidy status (Diploid vs. Aneuploid).

Visual Summary

The dot plot effectively illustrates condition-specific expression profiles for surfaceome markers in epithelial cells.

Biological Interpretation

The identified condition-specific surfaceome markers offer critical biological insights into breast cancer heterogeneity and normal mammary gland function.

These markers collectively provide a molecular signature of TNBC's aggressive, often mesenchymal, and stem-like characteristics.

Clinical or Translational Implications

The identification of condition-specific surfaceome markers in breast cancer epithelial cells holds significant clinical and translational potential.

References:

[1] GeneCards - ESR1. Available at: https://www.genecards.org/cgi-bin/carddisp.pl?gene=ESR1

[2] PubMed - SLC7A5 breast cancer. Available at: https://pubmed.ncbi.nlm.nih.gov/?term=SLC7A5+breast+cancer

[3] GeneCards - PIGR. Available at: https://www.genecards.org/cgi-bin/carddisp.pl?gene=PIGR

[4] GeneCards - CD44. Available at: https://www.genecards.org/cgi-bin/carddisp.pl?gene=CD44

[5] GeneCards - SPP1. Available at: https://www.genecards.org/cgi-bin/carddisp.pl?gene=SPP1

[6] NCI - CAR T-Cell Therapy. Available at: https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/car-t-cells

16. Macrophage Condition-Specific Surfaceome Markers in Breast Cancer

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies condition-specific surfaceome markers for Macrophages across different breast cancer subtypes (ER+, HER2+, TNBC) and Normal breast tissue. The results are presented as a dot plot, where each dot represents a marker gene's expression within Macrophage populations of individual patient samples. The size of the dot indicates the fraction of cells expressing the gene, while the color intensity reflects the mean expression level in those cells. This approach specifically focuses on surface proteins, which are highly relevant for understanding cell-cell interactions and identifying potential therapeutic targets.

Visual Summary

The dot plot clearly segregates Macrophage populations based on their surfaceome marker expression profiles across the different conditions.

Biological Interpretation

The observed condition-specific surfaceome markers underscore the profound plasticity and contextual adaptation of macrophages within the diverse microenvironments of normal breast tissue and different breast cancer subtypes.

Clinical or Translational Implications

The identification of condition-specific surfaceome markers provides valuable insights for potential clinical and translational applications.

17. Fibroblast Condition-Specific Surfaceome Markers in Breast Cancer Subtypes

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis aimed to identify condition-specific surfaceome markers in Fibroblasts across different breast cancer subtypes (ER+/HER2+, Normal, TNBC) from single-cell RNA-seq data. The plot_markers_and_expression_dot tool was used to visualize the expression of these markers. The analysis focused on surfaceome genes, meaning the identified markers are membrane-bound, making them highly relevant for cell surface-based applications. Markers common to three or more conditions were removed to emphasize condition specificity.

Visual Summary

The dot plot visualizes the expression of fibroblast surfaceome markers across individual samples, grouped by breast cancer condition (ER+/HER2+, Normal, TNBC). Each dot represents the expression of a specific gene (column) within a sample (row). The size of the dot indicates the fraction of cells in that sample expressing the gene, while the color intensity (red scale) represents the mean expression level of the gene in the expressing cells.

Key observations from the plot include:

Biological Interpretation

The analysis reveals significant condition-specific expression patterns of surfaceome markers in fibroblasts, highlighting their diverse roles within the breast cancer tumor microenvironment (TME).

This robust TNBC-specific fibroblast signature underscores the pivotal role of CAFs in creating a permissive and pro-tumorigenic microenvironment in this aggressive breast cancer subtype.

Clinical or Translational Implications

The identification of condition-specific surfaceome markers in fibroblasts carries significant clinical and translational potential, particularly for TNBC.

18. TNBC 특이적 CD4+ T 세포 표면 마커 분석

Report figure

[Analysis Visualization Results]...

Analysis Overview

본 분석은 단일 세포 RNA 시퀀싱 데이터에서 얻은 AnnData를 활용하여 CD4+ T 세포의 컨디션(예: 유방암 아형) 특이적 표면 마커를 식별하고 시각화합니다. 사용된 도구는 plot_markers_and_expression_dot으로, 각 샘플 그룹에서 마커 유전자의 평균 발현량과 발현 세포의 비율을 점도표(dot plot) 형태로 보여줍니다. 특히, 표면 마커(surfaceome markers)에 초점을 맞춰 최대 30개의 마커를 각 컨디션에서 식별하여 시각화하였습니다.

Visual Summary

제공된 점도표는 CD4+ T 세포에서 다양한 표면 마커의 발현 패턴을 보여줍니다. 각 행은 개별 환자 샘플을 나타내며, 각 열은 특정 유전자 마커를 나타냅니다. 점의 크기는 해당 그룹 내에서 유전자를 발현하는 세포의 비율(Fraction of cells in group, %)을 나타내고, 색상의 강도(빨간색 농도)는 해당 그룹 내에서 유전자의 평균 발현량(Mean expression in group)을 나타냅니다.

주요 관찰 결과는 다음과 같습니다:

Biological Interpretation

TNBC 샘플에서 고발현되는 CD4+ T 세포의 표면 마커들은 이 종양 미세환경에서 CD4+ T 세포의 활성화, 기능적 상태, 그리고 주변 세포와의 상호작용에 대한 중요한 단서를 제공합니다.

종합적으로, TNBC 샘플에서 고도로 발현되는 CD4+ T 세포 표면 마커들은 이들 세포가 활성화되고, 주변 미세환경과 상호작용하며, 특정 면역 반응을 조율하고 있음을 시사합니다. 이들의 발현 패턴은 TNBC의 염증성 미세환경과 CD4+ T 세포의 복합적인 역할(항종양성 또는 전종양성)을 반영할 수 있습니다.

Clinical or Translational Implications

이러한 TNBC 특이적 CD4+ T 세포 표면 마커의 발견은 다음과 같은 임상적 또는 중개적 의미를 가집니다:

19. Dysregulation of Cell Cycle Gene Expression in Breast Cancer Epithelial Cells Across Subtypes

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the "expressing cell fraction" of selected cell cycle pathway genes within epithelial cells across different breast cancer conditions (ER+, HER2+, TNBC) and Normal breast tissue. The expressing cell fraction represents the proportion of cells within each sample that show detectable expression of a given gene. This provides insight into the prevalence of specific cell cycle activities or states within the epithelial cell population of each condition. The objective is to identify statistically significant differences in the expression prevalence of these genes, highlighting potential mechanisms of cell cycle dysregulation in different breast cancer subtypes.

Visual Summary

The box plots illustrate the distribution of expressing cell fractions for 24 cell cycle-related genes across four conditions: ER+ (Estrogen Receptor positive), HER2+ (Human Epidermal growth factor Receptor 2 positive), Normal, and TNBC (Triple-Negative Breast Cancer).

Key visual observations include:

Subtype-Specific Patterns:

Biological Interpretation

The observed patterns of cell cycle gene expression fraction in epithelial cells provide strong biological insights into the distinct proliferative behaviors of breast cancer subtypes.

Contextual Roles of Signaling Molecules:

Clinical or Translational Implications

These findings have several important clinical and translational implications:

References

  1. MCM Proteins (General): https://www.genecards.org/cgi-bin/carddisp.pl?gene=MCM7 (Example for MCM7, similar roles for other MCMs)
  2. PCNA: https://www.genecards.org/cgi-bin/carddisp.pl?gene=PCNA
  3. MYC: https://www.genecards.org/cgi-bin/carddisp.pl?gene=MYC
  4. PTTG1: https://www.genecards.org/cgi-bin/carddisp.pl?gene=PTTG1
  5. HDAC1: https://www.genecards.org/cgi-bin/carddisp.pl?gene=HDAC1
  6. CDK1: https://www.genecards.org/cgi-bin/carddisp.pl?gene=CDK1
  7. CDKN2A/B/C (General): https://www.genecards.org/cgi-bin/carddisp.pl?gene=CDKN2A (Example for CDKN2A, similar roles for other CDKNs)
  8. SFN (14-3-3 sigma): https://www.genecards.org/cgi-bin/carddisp.pl?gene=SFN
  9. GADD45B: https://www.genecards.org/cgi-bin/carddisp.pl?gene=GADD45B
  10. SMAD3 and TGF-beta signaling in cancer: https://pubmed.ncbi.nlm.nih.gov/?term=SMAD3+TGF-beta+breast+cancer+tumor+suppressor
  11. TGFB2 and breast cancer: https://pubmed.ncbi.nlm.nih.gov/?term=TGFB2+breast+cancer+EMT

20. Gene Ontology (GSA) Analysis of Epithelial Cells in Breast Tissue Across Conditions

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Gene Ontology (GSA) enrichment results for Epithelial cells across different conditions (Diploid, ER+, HER2+, Normal, TNBC). Each bar plot shows pathways significantly enriched when Epithelial cells from a specific condition are compared against Epithelial cells from all other conditions combined ("_vs_others"). The enrichment is displayed as -log(p-val) and -log(q-val), where higher values indicate greater statistical significance. The aim is to identify condition-specific biological processes and pathways that characterize Epithelial cell states in the context of breast tissue and cancer.

Visual Summary

The provided visualizations consist of five bar plots, each representing the top enriched Gene Ontology (GO) terms for Epithelial cells in a specific condition (Diploid, ER+, HER2+, Normal, TNBC) compared to all other conditions.

Biological Interpretation

Epithelial Cells in Diploid Condition (Diploid_vs_others)

Epithelial cells identified as Diploid show significant enrichment in pathways related to Estrogen signaling pathway and Breast cancer. This suggests that even within diploid epithelial cells, pathways critical for breast cancer development and progression, particularly those driven by estrogen, are active. Other enriched terms like Ribosome and Apoptosis point to active protein synthesis and regulated cell death mechanisms, which are fundamental to both normal cellular homeostasis and early stages of cancer. The appearance of various 'disease' terms (e.g., Colorectal cancer, Kaposi sarcoma) highlights that these diploid cells may still harbor certain pro-oncogenic or stress-response mechanisms that are broadly implicated in diverse pathologies.

Epithelial Cells in ER+ Condition (ER+_vs_others)

Epithelial cells from ER+ breast cancer show a strong enrichment for terms related to metabolic reprogramming and protein homeostasis. Key enriched pathways include:

Epithelial Cells in HER2+ Condition (HER2+_vs_others)

Similar to ER+ cells, HER2+ Epithelial cells exhibit prominent enrichment in pathways related to metabolism and protein processing:

Epithelial Cells in Normal Condition (Normal_vs_others)

Epithelial cells from normal breast tissue show enrichment in fundamental cellular maintenance processes when compared to other cancer conditions:

Epithelial Cells in TNBC Condition (TNBC_vs_others)

Epithelial cells from Triple-Negative Breast Cancer (TNBC) show a distinct and expected enrichment for processes driving rapid proliferation:

Cross-Condition Observations

Clinical or Translational Implications

The condition-specific pathway enrichments in Epithelial cells offer valuable insights for clinical and translational applications:

21. 유방암 아형별 상피세포 유전자 세트 농축 분석 (GSEA)

Report figure

[Analysis Visualization Results]...

Analysis Overview

본 분석은 Diploid 세포, ER+ 유방암, HER2+ 유방암, 정상 유방 조직 및 삼중 음성 유방암(TNBC) 등 다양한 조건의 상피세포에 대한 유전자 세트 농축 분석(GSEA) 결과를 제시합니다. 각 조건은 나머지 모든 다른 조건과 비교되었습니다(vs_others). 이 점 플롯은 120개의 선별된 유전자 세트에 대한 정규화된 농축 점수(NES, 빨간색은 농축, 파란색은 고갈)와 통계적 유의성(-log(p-val), 점 크기)을 시각화합니다. RdBu_r 컬러 맵이 사용되었으며, 빨간색은 양의 NES를, 파란색은 음의 NES를 나타냅니다.

Visual Summary

이 점 플롯은 유방암 아형 및 정상 조직의 상피세포에서 다양한 생물학적 경로의 농축 패턴을 효과적으로 보여줍니다.

Biological Interpretation

유방암 상피세포의 일반적인 암 특징

많은 핵심 암 특징과 관련된 경로들이 ER+, HER2+, TNBC 상피세포 전반에 걸쳐 광범위하게 농축되어 있으며, 종종 높은 통계적 유의성을 보입니다:

아형 특이적 패턴 및 독특한 생물학적 특징

기타 주목할 만한 경로

Clinical or Translational Implications

22. Discussion

This single-cell RNA sequencing analysis provides a high-resolution view of the breast tissue microenvironment, elucidating distinct cellular states and interactions across normal tissue and three major breast cancer subtypes: ER+, HER2+, and TNBC. A primary finding is the profound genomic instability within tumor-originating epithelial cells. CNV analysis clearly demonstrates widespread aneuploidy in malignant epithelial cells, contrasting sharply with the diploid state of normal epithelial and stromal/immune cells. Recurrent amplifications of established oncogenes, such as *ERBB2* on 17q12 in HER2+ cancers and *MYC* on 8q in various subtypes, validate the molecular classification and underscore key drivers of oncogenesis. The observed heterogeneity in ploidy within ER+ tumors highlights the diverse genomic evolutionary paths even within a single subtype, implying varied clinical behaviors and therapeutic responses.

The immune microenvironment exhibits remarkable subtype-specific alterations. TNBC samples are characterized by increased infiltration of cytotoxic T cells (T_Cyto) and ILC1s, consistent with its 'inflamed' phenotype and better response rates to immunotherapies. However, a significant fraction of T cells in ER+ and HER2+ tumors remain 'unassigned,' suggesting the presence of novel or atypical T cell states that warrant further investigation, as they could represent immune evasion mechanisms or dysfunctional effectors. Macrophage populations show a complex reprogramming; while M1-like macrophages persist across cancer subtypes, there is a notable decrease in M2B macrophages and variable presence of other M2 subsets. This challenges a simplistic M1-to-M2 polarization switch, indicating a more nuanced interplay of macrophage phenotypes. Importantly, TNBC-associated macrophages display a unique surfaceome signature (e.g., high FCGR3A, TNFSF13B, SLC2A3, CD86), pointing to distinct functional adaptations in this aggressive subtype.

The stromal compartment also undergoes significant remodeling. Fibroblasts from TNBC exhibit a highly activated cancer-associated fibroblast (CAF) signature, characterized by strong expression of surface markers like FAP, MMP14, PDGFRB, and LY6E. These CAFs are crucial orchestrators of extracellular matrix dynamics and pro-tumorigenic signaling, distinct from their quiescent counterparts in normal tissue. Cell-cell interaction (CCI) analysis reveals shared pro-tumorigenic interactions across all cancer subtypes, including NAMPT-NOX2, PLAU-PLAUk, PPIA-BSG, TYROBP-CD44, and the immunosuppressive LGALS9-HAVCR2 (Galectin-9-TIM-3) axis, primarily between macrophages and aneuploid epithelial cells. HER2+ tumors show unique cholesterol metabolism-related interactions and active angiogenesis (VEGFA-NRP1), while TNBC interactions highlight desmosomal changes and Notch signaling. In contrast, normal tissue features homeostatic integrin-ECM and growth factor signaling between fibroblasts and diploid epithelial cells.

Gene Ontology (GSA) and Gene Set Enrichment Analysis (GSEA) reinforce these cellular observations. Cancer epithelial cells, especially TNBC, show widespread enrichment of cell cycle, DNA replication, and metabolic reprogramming pathways (e.g., oxidative phosphorylation, lipid metabolism), reflecting their high proliferative and bio-synthetic demands. Conversely, normal epithelial cells are enriched in fundamental processes of gene expression and protein homeostasis. The strong enrichment of 'PD-L1 expression and PD-1 checkpoint pathway in cancer' in TNBC and HER2+ epithelial cells further supports the potential for immunotherapy in these subtypes. The consistent appearance of pathways related to protein processing and quality control across all cancer subtypes, along with altered lipid metabolism, underscores the fundamental adaptive mechanisms employed by cancer cells. The persistent M1 macrophage populations and the variable nature of M2 subsets, rather than a definitive M1-to-M2 switch, represent a notable deviation from some generalized literature models and emphasize the need for context-specific macrophage characterization.

Hypotheses:

  1. The high proportion of ILC1s and cytotoxic T cells in TNBC contributes to its 'immunogenic' phenotype, but their anti-tumor efficacy is dampened by specific immunosuppressive interactions (e.g., LGALS9-HAVCR2 axis, TGF-β signaling) and the metabolic adaptation of tumor-associated macrophages.
  2. The 'unassigned' T cell populations observed in ER+ and HER2+ breast cancers represent distinct exhausted or anergic T cell states induced by their specific tumor microenvironments, contributing to immune evasion in these less immunogenic subtypes.
  3. The unique surfaceome signature of TNBC-associated fibroblasts (e.g., FAP, MMP14, PDGFRB, LY6E) defines a highly aggressive CAF phenotype that actively drives extracellular matrix remodeling, angiogenesis, and immunosuppression, making these specific markers critical for therapeutic targeting.
  4. Dysregulated cholesterol and fatty acid metabolism pathways, notably active in HER2+ epithelial cells and their interactions with macrophages, serve as critical vulnerabilities for tumor growth and survival, offering novel opportunities for combination therapies alongside anti-HER2 treatments.
  5. The reduced expression of lymphoid tissue inducer (LTI) cells and regulatory ILCs in breast cancer conditions compared to normal tissue indicates an impaired capacity for proper lymphoid tissue organization within the tumor microenvironment, contributing to an ineffective anti-tumor immune response.

Potential therapeutic targets:

  1. TIM-3 (HAVCR2) / Galectin-9 (LGALS9) Immune Checkpoint Axis: This axis represents a critical immunosuppressive pathway that consistently appears as a significant interaction between macrophages/aneuploid epithelial cells and immune cells across all breast cancer subtypes, suggesting it's a broad mechanism of immune evasion. Evidence: Cell-cell interaction analysis (Section 12) shows LGALS9-HAVCR2 as a prominent and highly significant interaction in ER+, HER2+, and TNBC, particularly between macrophages and aneuploid epithelial cells, indicating active suppression of anti-tumor immunity. Validation: Evaluate TIM-3 blocking antibodies in preclinical breast cancer models, especially in combination with existing standard-of-care therapies (e.g., anti-HER2 agents, chemotherapy, or other checkpoint inhibitors), to assess their impact on T cell activation, immune infiltration, and tumor regression.
  2. TGF-β signaling pathway (TGFB1-TGFBR1 / integrin_aVb6_complex): TGF-β is a potent immunosuppressive cytokine that promotes tumor growth, metastasis, and immune evasion. Its active signaling is notably prominent in the HER2+ tumor microenvironment and implicated in broader cancer progression. Evidence: Cell-cell interaction analysis (Section 13) specifically highlights strong TGFB1-TGFbeta_receptor1 interactions between macrophages and aneuploid epithelial cells in HER2+ breast cancer. The TGFB1_integrin_aVb6_complex is also noted, suggesting active latent TGF-β1 activation. GSA results (Section 20) show decreased SMAD3 (a downstream effector) in cancer epithelial cells, potentially indicating pathway bypass or altered regulation, while TGFB2 expression is increased in TNBC epithelial cells. Validation: Test TGF-β inhibitors (e.g., receptor kinase inhibitors) or antibodies targeting integrin αvβ6 in HER2+ and TNBC preclinical models, alone or in combination with anti-HER2 therapies or immunotherapies, to reverse immune suppression, reduce tumor growth, and prevent metastasis.
  3. Cancer-Associated Fibroblast (CAF) Activation Markers (e.g., FAP, MMP14, PDGFRB): CAFs are crucial drivers of tumor progression by remodeling the extracellular matrix, promoting angiogenesis, and fostering an immunosuppressive environment. TNBC fibroblasts show a highly activated and distinct pro-tumorigenic phenotype. Evidence: Fibroblast condition-specific surfaceome markers (Section 17) demonstrate strong and prevalent expression of FAP, MMP14, PDGFRB, and LY6E in TNBC fibroblasts, distinguishing them from normal and other cancer subtypes. Cell-cell interaction analysis (Section 14) also underscores extensive integrin-ECM interactions involving fibroblasts across cancer conditions. Validation: Develop and test FAP-targeted therapies (e.g., antibody-drug conjugates, CAR-T cells) or inhibitors for MMP14 or PDGFRB in TNBC preclinical models to evaluate their efficacy in reducing stromal support, tumor invasion, and metastasis, potentially in combination with chemotherapy or immunotherapy.
  4. MYC / Cell Cycle Kinases (CDK1, HDAC1): TNBC is characterized by aggressive proliferation driven by dysregulated cell cycle progression and oncogene activation. Targeting these fundamental processes offers broad therapeutic potential. Evidence: Epithelial cell CNV analysis (Section 4) frequently identifies amplifications on chromosome 8q, a region harboring the *MYC* oncogene. GSA and GSEA results (Sections 20 & 21) show strong enrichment of 'Cell cycle' and 'DNA replication' pathways in TNBC epithelial cells. Box plots of cell cycle genes (Section 19) reveal significantly elevated expressing cell fractions of MCM proteins, PCNA, MYC, PTTG1, CDK1, and HDAC1 in TNBC epithelial cells compared to normal tissue. Validation: Evaluate the efficacy of MYC inhibitors (e.g., small molecules, peptide inhibitors) or inhibitors of key cell cycle kinases like CDK1 or HDAC1 in TNBC models. Assess their ability to suppress proliferation and induce apoptosis, potentially in combination with immunotherapies to counteract the 'cold' tumor effect in some TNBCs or other targeted agents.

Follow-up validation ideas:

  1. Perform multi-modal spatial transcriptomics and proteomics (e.g., CODEX, IMC) on breast cancer tissue sections to validate the physical proximity and functional significance of identified cell-cell interaction pairs (e.g., LGALS9-HAVCR2, NAMPT-NOX2, PLAU-PLAUk) in situ, correlating with tumor progression and immune infiltration.
  2. Utilize flow cytometry or mass cytometry (CyTOF) on dissociated tumor and normal breast tissue samples from independent cohorts to quantify the expression of key surface markers (e.g., ICOS, TNFRSF1B for T cells; FCGR3A, TNFSF13B, SLC2A3 for macrophages; FAP, MMP14, LY6E for fibroblasts) and to phenotype the 'unassigned' T cell populations identified in ER+ and HER2+ tumors.
  3. Conduct in vitro co-culture experiments using patient-derived tumor organoids or cell lines with specific immune and stromal cell subsets, employing gene knockdown/overexpression or targeted inhibitors (e.g., TGF-β inhibitors, FAP inhibitors, TIM-3 blockers) to functionally validate the causal roles of identified cell-cell interactions and metabolic pathways in tumor growth, invasion, and immune suppression.
  4. Investigate the functional consequences of altered lipid metabolism (e.g., targeting SLC7A5 in HER2+ epithelial cells or exploring cholesterol synthesis inhibitors) using metabolic tracing (e.g., 13C glucose/glutamine) in HER2+ breast cancer cell lines or organoids to understand their impact on tumor cell proliferation and survival.
  5. Validate the prognostic and predictive value of specific CNV patterns (e.g., ERBB2, MYC amplifications) and the identified cell population shifts (e.g., ILC1/T_Cyto levels in TNBC, specific macrophage subsets) in large, independent clinical cohorts of breast cancer patients, correlating with survival outcomes and response to targeted or immunotherapies.

Limitations:

This report is based on single-cell RNA sequencing data, from which certain analyses like CNV inference and cell-cell interaction prediction are computational estimations requiring orthogonal experimental validation. The correlative nature of many observed population shifts and pathway enrichments necessitates functional studies to establish causality. While cell type annotations are robust, the classification of certain immune cell subsets (e.g., macrophage polarization, 'unassigned' T cells) might not fully capture the continuous spectrum of cellular states or atypical phenotypes that exist in vivo. The generalizability of these findings may be influenced by cohort specifics, and further validation in larger, diverse patient populations and preclinical models is essential for clinical translation.

23. Query List

  1. Show UMAPs for condition, sample, major cell type, minor cell type, ploidy_dec, and celltype_subset in two columns and save the result.
  2. Show major cell type scores on UMAP and save the result.
  3. Show a marker expression dot plot for celltype_subset. SET target_cell = None and var_group_rotation = 45. Leave all other arguments at their default values and save the result.
  4. Select Epithelial cells, show a CNV heatmap grouped by sample together with a summary of regions with significantly amplified copy numbers, and save the results.
  5. Show UMAPs of CNV patterns colored by major cell type, minor cell type, ploidy results, condition, and sample in two columns and save the result.
  6. Show a population bar plot of minor cell types and save the result.
  7. Show a population bar plot of T cell subsets and save the result.
  8. Show box plots of T cell subset populations with statistically significant differences between conditions, if any. Choose ncols based on the total number of panels and save the result.
  9. Show a population bar plot of macrophage subsets and save the result.
  10. Show box plots of macrophage subset populations with statistically significant differences between conditions, if any. Choose ncols based on the total number of panels and save the result.
  11. Select Epithelial cells, show their ploidy populations as a bar plot, and save the result.
  12. Show cell-cell interaction patterns involving Epithelial cells, fibroblasts, macrophages, T cells, and other relevant cell types. Select at most 80 cell-cell interactions per group and save the result.
  13. Select only genes associated with immune checkpoint and cell cycle pathways, show cell-cell interactions for these genes, and save the result.
  14. Find cell-cell interactions involving major immune and stromal cells that differ significantly between conditions, show them as a dot plot, and save the result. Set max_n_items_per_group to 60.
  15. Extract condition-specific markers for Epithelial cells, show their expression as a dot plot, and save the result. Use only surfaceome markers, with at most 50 markers per condition.
  16. Extract condition-specific markers for Macrophage to show the markers expression as a dot plot, and save the result. Use only surfaceome markers, with at most 30 markers per condition.
  17. Extract condition-specific markers for Fibroblast to show the markers expression as a dot plot, and save the result. Use only surfaceome markers, with at most 30 markers per condition.
  18. Extract condition-specific markers for T cell CD4+ to show the markers expression as a dot plot, and save the result. Use only surfaceome markers, with at most 30 markers per condition.
  19. Among cell cycle pathway genes, select those with statistically significant expression differences between conditions in Epithelial cells, show box plots, and save the result. Set max_n_items_to_plot to 24 and choose ncols based on the total number of panels for an overall width-to-height ratio of approximately 2:3.
  20. Show Gene Ontology (GSA) analysis results for Epithelial cells as a bar plot and save the result.
  21. Show Gene Set Enrichment Analysis results for Epithelial cell as a dot plot and save it. Set the color map to RdBu_r and n_pws_to_show to 120.
↑ Top